文献速递淋巴瘤

中国弥漫大B细胞淋巴瘤P53表达的病理判读标准及其预后价值研究

[Investigation for pathological interpretation criteria and its prognostic value for P53 expression in Chinese diffuse large B-cell lymphoma].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2022-01-01

研究纳入北京高博博仁医院51例同时行免疫组化与二代测序的弥漫大B细胞淋巴瘤病例,发现P53缺失(<1%)或弥漫(>80%)表达提示TP53突变高风险,免疫组化预测敏感性95.7%、特异性96.4%;另纳入北京大学肿瘤医院131例患者多因素分析显示TP53突变高风险是总生存的独立危险因素(HR=2.612,95%CI 1.145~5.956,P=0.022)。

要点

  • P53免疫组化缺失(<1%)或弥漫(>80%)表达提示TP53突变高风险。
  • 免疫组化预测TP53突变敏感性95.7%、特异性96.4%。
  • TP53突变高风险是总生存的独立危险因素(HR=2.612,P=0.022)。

核心结论

  • 免疫组化P53缺失(<1%)或弥漫(>80%)表达提示TP53突变高风险,预测敏感性与特异性高。
  • TP53突变高风险是预后不良的独立影响因素。

研究设计与样本

  • 研究纳入北京高博博仁医院2021年1月至2021年12月同时行免疫组化与二代测序的弥漫大B细胞淋巴瘤病例51例。
  • 另纳入北京大学肿瘤医院2016年6月至2019年9月有完整随访资料的弥漫大B细胞淋巴瘤患者131例,制作组织芯片行P53免疫组化评估预后。

主要发现

  • 51例中TP53突变高风险23例(7例缺失、16例弥漫),二代测序证实22例存在TP53突变。
  • TP53突变低风险组28例中仅1例经二代测序证实有TP53突变。
  • 二代测序共检出26个TP53突变位点,等位基因突变频率61.57%(13.41%~86.25%)。
  • P53弥漫组检出16个错义突变、2个剪切位点突变;缺失组检出6个截短突变、1个剪切位点突变;不均一组检出1个截短突变。
  • 131例中免疫组化显示29.0%(38/131)为TP53突变高风险(17例弥漫、21例缺失),多因素分析HR=2.612,95%CI 1.145~5.956,P=0.022。

关键数值与推荐

  • P53免疫组化缺失定义为<1%,弥漫定义为>80%,不均一定义为1%~80%。
  • 缺失及弥漫表达归为TP53突变高风险组。
  • 免疫组化预测TP53突变敏感性95.7%,特异性96.4%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the feasibility of predicting TP53 mutation risk by immunohistochemical staining (IHC) pattern of P53 in Chinese diffuse large B-cell lymphoma (DLBCL) and its correlation with a prognostic difference. Methods: Between January 2021 and December 2021, 51 DLBCL cases at Beijing Boren Hospital were gathered. These cases had both IHC and next-generation sequencing (NGS) results. IHC classified the P53 protein expression pattern into a loss (<1% ) , diffuse (>80% ) , and heterogeneous (1% -80% ) . The sensitivity and specificity of the predicting TP53 mutation by IHC were assessed by comparing the results of the NGS, and the TP53 high mutation risk group included both loss and diffuse expression of P53. From June 2016 to September 2019, Peking University Cancer Hospital collected 131 DLBCL cases with thorough clinicopathological and follow-up data. From their tumor blocks, tissue microarray blocks were made for IHC evaluation of P53 expression pattern, and prognosis effect of P53 studies. Results: Among 51 cases with both IHC and NGS results, 23 cases were classified as TP53 high mutation risk (7 cases loss and 16 cases diffuse) , 22/23 cases were proved with mutated TP53 by NGS. Only 1 of the 28 cases classified as TP53 low mutation risk was proved with mutated TP53 by NGS. IHC had a sensitivity and specificity of 95.7% and 96.4% for predicting TP53 mutation. NGS identified a total of 26 TP53 mutations with a mutation frequency of 61.57% (13.41% -86.25% ) . In the diffuse group, 16 missense mutations and 2 splice mutations were detected; 6 truncating mutations and 1 splice mutation were detected in the loss group; 1 truncating mutation was detected in the heterogeneous group. Multivariate analysis demonstrated that TP53 cases with high mutation risk have impartial adverse significance for the 131 patients included in survival analysis (HR=2.612, 95% CI 1.145-5.956, P=0.022) . Conclusion: IHC of P53 exhibiting loss (<1% ) or diffuse (>80% ) pattern indicated TP53 high mutation risk, IHC can predict TP53 mutation with high specificity and sensitivity. TP53 high mutation risk is an independent predictor for adverse survival. 目的: 探索在国人弥漫大B细胞淋巴瘤(DLBCL)中免疫组织化学染色(IHC)检测P53蛋白表达状态预测TP53基因突变风险的能力,以及P53表达差异的预后评估价值。 方法: 收集北京高博博仁医院2021年1月至2021年12月同时进行二代测序(NGS)和IHC检测的DLBCL病例51例,依据P53的IHC染色将P53蛋白表达状态分为缺失(<1%)、弥漫(>80%)和不均一(1%~80%)3组,将缺失及弥漫表达归为TP53突变高风险组;与NGS结果对比分析IHC预测TP53突变风险的敏感性和特异性。收集北京大学肿瘤医院2016年6月至2019年9月有完整随访资料的DLBCL患者131例,制作组织芯片并通过IHC检测P53表达,评估P53表达差异的预后价值。 结果: 51例同时行IHC和NGS检测的病例中,TP53突变高风险23例(7例缺失,16例弥漫),NGS证实22例存在TP53突变;TP53突变低风险组28例,仅1例证实有TP53突变。IHC预测TP53突变风险敏感性95.7%,特异性96.4%。NGS共检出26个TP53突变位点,等位基因突变频率为61.57%(13.41%~86.25%),P53弥漫组检出16个错义突变、2个剪切位点突变;缺失组检出6个截短突变、1个剪切位点突变;不均一组检出1个截短突变。纳入预后分析的131例DLBCL患者中,IHC显示29.0%(38/131)为TP53突变高风险(17例弥漫、21例缺失)。多因素分析显示TP53突变高风险(HR=2.612,95% CI 1.145~5.956,P=0.022)是影响总生存的独立危险因素。 结论: IHC检测P53蛋白表达缺失(<1%)或弥漫(>80%)TP53突变风险高,IHC预测TP53突变的敏感性与特异性高,TP53突变高风险是预后不良的独立影响因素。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Shi YF, Gao ZF, Li XH, et al. [Investigation for pathological interpretation criteria and its prognostic value for P53 expression in Chinese diffuse large B-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 36709106. doi:10.3760/cma.j.issn.0253-2727.2022.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。